-- グラファイト・ワン社(GPH.V)は月曜日、グラファイト・クリーク・プロジェクトは米国のFAST-41連邦許認可プログラムの下で「進行中」であり、必要なすべての連邦審査を予定通りに進めていると発表した。 アラスカ州ノームの北60kmに位置するグラファイトクリーク・プロジェクトは、露天掘り黒鉛鉱山および関連鉱物処理プラントの建設計画であり、2025年6月2日にFAST-41の「対象プロジェクト」として承認されました。 60日間の調整プロジェクト計画(CPP)策定プロセスを経て、詳細な許認可スケジュールが2025年8月5日に公表されました。CPPでは、必要な連邦環境審査および認可手続きに13.5ヶ月の期間が設けられ、完了予定日は2026年9月29日となっています。 「FAST-41は、環境基準や規制基準を変更することなく、複数の連邦機関にわたる迅速性、予測可能性、説明責任の向上という、まさに設計目的を達成しました」と、最高経営責任者のアンソニー・ヒューストン氏は述べています。 「FAST-41は、調整された公開スケジュールを策定し、関係機関を早期に結集させることで、米国最大の黒鉛鉱床の開発を加速させ、リチウムイオン電池の負極材をはじめとする様々な技術分野における重要な黒鉛製品の、安全な国内サプライチェーンの構築を促進します。」 グラファイト・ワン社の株価は、金曜日のトロント証券取引所ベンチャー市場で0.03ドル下落し、1.15ドルで取引を終えた。
Related Articles
Stifel Canada Hikes Aritzia Price Target to $158.00
Stifel Canada is expecting another strong quarter from Aritzia (ATZ.TO) when it reports its fiscal fourth-quarter earnings on May 7.Analyst Martin Landry, who is raising his price target on the company's shares by $8.00 to $158.00 and maintaining a buy rating, is also hiking comparable sales growth expectation by 700bps to 21% Y/Y, higher than consensus of 18%."We expect Aritzia to introduce a FY27 guidance higher than current consensus expectations, potentially driving upwards earnings revisions," Landry adds. Aritzia shares touched an all-time high on Friday as investors are pricing the company's strong operational performance.Landry also expects earnings per share growth of 34% Y/Y in fiscal 27, higher than peers.Price: $139.87, Change: $-3.34, Percent Change: -2.33%
HCA Healthcare Pressure Expected to Persist Through Q2 on Managed Care Rotation, RBC Says
HCA Healthcare (HCA) may face near-term pressure through at least the first half as investors rotate toward managed care, although better trends in March and in-line exchange dynamics support the longer-term outlook, RBC Capital Markets said.The company's weaker-than-expected Q1, driven by lower respiratory volume and weather-related disruption, has increased near-term concern around hospital volumes and patient mix.RBC said in a Sunday note that it expects Friday's share price decline to persist through Q2 as management works to demonstrate execution against growth targets and as investors await further clarity on the impact of ePTC expiry.The investment firm said March volumes improved meaningfully while exchange-related pressure remains manageable. HIX declines reflect both lost volume and patients in grace periods already incorporated into bad debt reserves. Surgical and outpatient trends remain broadly consistent with its full-year outlook, according to the note.RBC reiterated its outperform rating and lowered its price target to $534 from $593, citing increased caution on near-term hospital volume and mix dynamics and a broader rotation toward managed care.Price: $439.41, Change: $+6.95, Percent Change: +1.61%
BluEnergies Announces DTC Eligibility
BluEnergies (BLU.V) shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (DTC), BluEnergies said on Monday.The company's shares recently began trading on the OTCQX Best Market under the ticker BLUGF, it added."Obtaining DTC eligibility marks an important step in expanding BLU's investor base and enhancing accessibility for shareholders," said chief executive Craig Steinke. "For investors, DTC eligibility is a key milestone that streamlines electronic trading and supports improved liquidity, which is especially important as we advance the development of our assets in the Harper Basin, Liberia and Gulf of America and continue to build long-term value across our portfolio."The company's shares were last seen down $0.09, or 3.1%, to $2.73 on the TSX Venture Exchange.Price: $2.73, Change: $-0.09, Percent Change: -3.19%